The Chemistry of Hope: Ketamine as a Turning Point in a Self-Harm Crisis

Published

2026-06-12

Keywords:

Ketamine Infusion, Intentional Self-Harm, Suicidal Ideation, Treatment Resistant Depression

Dimensions Badge

Issue

Section

CASE STUDY

Authors

  • Shradha Khatri AFMC

Abstract

Intentional Self-Harm (ISH) is a significant public health concern, especially in young adults, and is frequently associated with depressive disorders.[1] While medical stabilization is the first priority, timely Psychiatric care is critical for prevention of recurrence. Low-dose Ketamine has recently been reported to produce rapid antidepressant effects, including reduction of suicidal ideation. [2] This report is of an old case of Moderate Depressive Episode, presenting after ingesting approximately 30 tablets of Clonazepam following a familial conflict. After initial emergency medical care, persistent suicidal thoughts led to initiation of eight-sessions of intravenous Ketamine treatment protocol. Within 24 hours, suicidal ideation reduced significantly.  Ongoing treatment and psychotherapy were continued and there was a sustained improvement at six-week follow-up. Ketamine may be a useful rapid acting adjunct for rapid reduction of suicidal ideation in treatment resistant depression, offering a bridge to ongoing treatment.

How to Cite

Khatri, S. (2026). The Chemistry of Hope: Ketamine as a Turning Point in a Self-Harm Crisis. Indian Journal of Clinical Psychiatry. Retrieved from https://www.ijocp.com/index.php/IJOCP/article/view/270

Downloads

Download data is not yet available.

References

1. Hawton K, Bergen H, Kapur N, Cooper J, Steeg S, Ness J, et al. Clinical management and outcome of self-harm in young people: cohort study in England. BMJ. 2012;344:e316. Available from: doi:10.1136/bmj.e316

2. Wilkinson ST, Ballard ED, Bloch MH, Mathew SJ, Murrough JW, Feder A, et al. The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis. Am J Psychiatry. 2018;175(2):150–158.

3. Hetrick SE, Cox GR, Witt KG, Bir J, Rutherford S, Merry SN. Psychological interventions for self-harm in children and adults: a systematic review, meta-analysis, and meta-regression. BMJ Open. 2016;6(9):e011024.

4. Lundgren E, Andersson TM-L, Sköld CM, Jörgensen L, Ljung R. Risk factors for suicide and suicide attempts among patients with treatment-resistant depression: a nationwide nested case–control study. J Affect Disord. 2020;272:381–388.

5. Pardossi S, Fagiolini A, Cuomo A. Variations in BDNF and their role in the neurotrophic antidepressant mechanisms of ketamine and esketamine: a review. Int J Mol Sci. 2024;25(23):13098.

6. World Health Organization. International statistical classification of diseases and related health problems: alphabetical index. Geneva: World Health Organization; 2004.

7. Almeida MS, Sousa Filho LF, Rabello PM, Santiago BM. International Classification of Diseases–11th revision: from design to implementation. Rev Saude Publica. 2020;54:104.

8. Thase ME, Rush AJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry. 1997;58 Suppl 13:23–29.

9. Micallef-Trigona B. Comparing the effects of repetitive transcranial magnetic stimulation and electroconvulsive therapy in the treatment of depression: a systematic review and meta-analysis. Depress Res Treat. 2014;2014:135049.

10. Short B, Fong J, Galvez V, Shelker W, Loo CK. Side-effects associated with ketamine use in depression: a systematic review. Lancet Psychiatry. 2018;5(1):65–78.

Similar Articles

<< < 1 2 3 4 5 6 

You may also start an advanced similarity search for this article.